Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease.

Next Previous
Trial Profile

A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms APEX-PD
  • Sponsors IMPAX Laboratories

Most Recent Events

  • 25 Nov 2015 According to Impax Laboratories' media release, the European Commission has granted marketing approval for levodopa/carbidopa modified release combination (NUMIENT) for the symptomatic treatment of adult patients with Parkinson's disease.
  • 25 Sep 2015 According to Impax Laboratories' media release, the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending levodopa/carbidopa modified release combination (NUMIENT) for the symptomatic treatment of adult patients with Parkinson's disease.
  • 25 Apr 2015 Results comparing efficacy from APEX-PD, ADVANCE-PD and ASCEND-PD trials presented at the 67th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top